text_1: MEK inhibitors are effective treatments in RAS-driven mouse models of cancer.
text_2: Somatic mutations that activate phosphoinositide 3-kinase (PI3K) have been identified in the p110-alpha catalytic subunit (encoded by PIK3CA).